The green light for drugmaker Regeneron came after REGEN-COV2, a combination of two lab-made antibodies, was shown to reduce Covid-19-related hospitalizations or emergency room visits in patients with underlying conditions https://t.co/tH4NuVQiY3 pic.twitter.com/5aoLzvZu8w

— AFP News Agency (@AFP) November 22, 2020